Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Stem cells in breast cancer

Share :

EBCC 7

17 Nov 2011
Published: 22 Apr 2010
Views: 11359
Rating:
Save
Dr Robert Clarke - Paterson Institute for Cancer Research, University of Manchester, UK
Dr Clark discusses how cancer stem cells can be targeted by inhibiting the Notch signalling pathway.

Related Videos

ESMO 2024: Highlights and analysis
Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )
16 Sep 2024
Mutational-based treatment approach may significantly improve outcomes in...
Dr Andrea Botticelli - Sapienza Università di Roma, Rome, Italy
Mutational-based treatment approach may significantly improve outcomes in pretreated patients with metastatic solid tumours ( Dr Andrea Botticelli - Sapienza Università di Roma, Rome, Italy )
16 Sep 2024
ERBB2 amplifications across sex, race, and cancer types studied to guide HER2...
Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA
ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies ( Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA )
14 Sep 2024
Trastuzumab deruxtecan effective against brain metastases in HER2-positive...
Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer ( Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA )
14 Sep 2024
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA
Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )
12 Jul 2024
Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced...
Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA
Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant ( Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA )
26 Jun 2024
Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond...
Dr Dejan Juric - Massachusetts General Hospital, Boston, USA
Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer ( Dr Dejan Juric - Massachusetts General Hospital, Boston, USA )
3 Jun 2024
Addition of atezolizumab to chemotherapy after surgery does not improve...
Dr Heather McArthur - UT Southwestern Medical Center, Dallas, USA
Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer ( Dr Heather McArthur - UT Southwestern Medical Center, Dallas, USA )
26 Apr 2024
A combined PET-MRI scan could improve treatment for patients with early breast...
Dr Rosa Di Micco - San Raffaele Hospital, Milan, Italy
A combined PET-MRI scan could improve treatment for patients with early breast cancer ( Dr Rosa Di Micco - San Raffaele Hospital, Milan, Italy )
26 Apr 2024

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation